Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
$9.80
-$0.59(-1.49%)
At close: 4:00 PM EST
$9.80
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $24.06
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.45M
Market Cap
$1.47B
Enterprise Value$1.09B
Total Cash (Recent Filing)$319.14M
Total Debt (Recent Filing)$278.86M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 08, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding150,420,580
10 Day Avg. Volume2,900,754
30 Day Avg. Volume2,452,338
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-526.09
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$21.50Price Target Upside119.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IgA Nephropathy Proof‑of‑conceptBHV-1400 produced targeted reduction of disease-specific antibodies while sparing normal immunoglobulins and showed early clinical responses, supporting advancement into pivotal trials for IgA nephropathy.
Obesity Program Pivotal ReadoutCompletion of enrollment in the obesity trial preserves the path to a pivotal efficacy readout, creating a clear catalyst if topline results confirm meaningful weight-loss outcomes.
Tolerability Differentiation In EpilepsyOpakalim's Kv7 mechanism and open-label signals suggest comparable seizure reduction with fewer central nervous system side effects, which could allow differentiation based on tolerability and support uptake among prescribers prioritizing patient quality of life.
Bears Say
Competitive Commercial PressureA competitor's strong confirmatory results and favorable safety profile raise the commercial bar, making it harder for opakalim to capture meaningful market share.
Financing And Pipeline Reprioritization RiskManagement's reprioritization and reduced R&D spending to preserve capital signal potential for further program cuts or additional fundraising that could pressure the stock.
Second‑to‑market DisadvantageOpakalim's later development timeline and physician treatment inertia favoring an established product may limit initial adoption despite potential tolerability benefits.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $24.06 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.47B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is May 08, 2026 which is in 33 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Mar 02, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.188 by -$0.022.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.84.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,420,580 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.188. Following the earnings report the stock price went down -9.653%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.50 (119.39% Upside)
$21.50 (119.39% Upside)
Blogger Sentiment
Bearish
BHVN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.43%
12-Months-Change
Fundamentals
Return on Equity
-688.89%
Trailing 12-Months
Asset Growth
-26.61%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$21.50
▲(119.39% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
9.06% Mutual Funds
30.86% Other Institutional Investors
40.54% Public Companies and
Individual Investors